The Medicines Company (MDCO) Receives Analyst Rating

The Medicines Company (MDCO) : 5 brokerage houses believe that The Medicines Company (MDCO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

The Medicines Company (MDCO) : The most positive equity analysts on The Medicines Company (MDCO) expects the shares to touch $65, whereas, the least positive believes that the stock will trade at $43 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $51.6 with an expected fluctuation of $8.65 from the mean.


Also, In a research note released to the investors, Citigroup maintains its rating on The Medicines Company (NASDAQ:MDCO).The analysts at the brokerage house have a current rating of Neutral on the shares. In a recent information released to the investors, Citigroup raises the new price target from $43 per share to $44 per share. The rating by the firm was issued on August 1, 2016.

The Medicines Company (NASDAQ:MDCO): After opening at $37.62, the stock dipped to an intraday low of $37.255 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $38.3 and the buying power remained strong till the end. The stock closed at $37.88 for the day, a gain of 0.96% for the day session. The total traded volume was 675,043. The stocks close on the previous trading day was $37.52.

The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *